Royalty Pharma plc ( RPRX) - Stock Earnings
RPRX Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 7, 2025 BeforeMarket | - / - | 806.0 million | - / 806.0 million | 806.0 million |
RPRX Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2024Q4 | 208.0 million USD | 594.0 million USD |
| 2024Q3 | 544.0 million USD | 564.7 million USD |
| 2024Q2 | 102.0 million USD | 537.3 million USD |
| 2024Q1 | 4.8 million USD | 568.0 million USD |
| 2023Q4 | 494.3 million USD | 596.0 million USD |
RPRX Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2024 | 859.0 million USD | 2.3 billion USD |
| 2023 | 1.1 billion USD | 2.4 billion USD |
| 2022 | 42.8 million USD | 2.2 billion USD |
| 2021 | 478.8 million USD | 2.3 billion USD |
| 2020 | 495.2 million USD | 2.1 billion USD |
RPRX
List: Challengers
Price: $33.64
Dividend Yield: 2.72%
Forward Dividend Yield: 2.63%
Payout Ratio: 56.00%
Dividend Per Share: 0.88 USD
Earnings Per Share: 1.91 USD
P/E Ratio: 17.45
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.0 million
Ebitda: -16.0 millionMarket Capitalization: 14.4 billion
Average Dividend Frequency: 4
Years Paying Dividends: 6
DGR3: 21.38%